How much funding has Rheos raised?

Rheos has raised $60.0M in total funding, most recently a Series A round.

Who are Rheos's investors?

Rheos's investors include Third Rock Ventures.

Where is Rheos headquartered?

Rheos is headquartered in Cambridge, Massachusetts, United States.

What industry is Rheos in?

Rheos operates in Biotech, Healthcare.

Rheos

Closed

Cambridge, United States · Founded 2018 · $60.0M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 11–50
Founded: 2018
Business Model: B2B

Website: rheosrx.com
Total Funding: $60.0M
Last Round: $60.0M Series AMar 2018
Rounds: 1

About

Rheos Medicines was a Cambridge, Massachusetts-based biotechnology company founded in 2018 by Third Rock Ventures with $60 million in Series A funding. The company was built around the emerging science of immunometabolism — the study of how metabolic pathways drive immune cell function and fate — to develop novel precision medicines for autoimmune and inflammatory diseases. Rheos developed a proprietary product engine that characterized the metabolic drivers of immune-mediated diseases, with initial focus on inflammatory bowel disease and related conditions. In December 2019, the company announced a major worldwide collaboration with Roche worth up to $793 million to discover new drugs in immunometabolism. Despite promising science and high-profile partnerships, Rheos shut down operations in February 2023.

Summary

Rheos is a Biotech company based in Cambridge, United States, founded in 2018. It has raised $60.0M in total across 1 round, most recently a $60.0M Series A round in Mar 2018. Investors include Third Rock Ventures.